Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo

Sean McCafferty, April Harris, Corin Kew, Tala Kassm, Lisa Lane, Jason Levine, Meisha Raven, Sean McCafferty, April Harris, Corin Kew, Tala Kassm, Lisa Lane, Jason Levine, Meisha Raven

Abstract

Background: Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective, randomized, double-masked, placebo-controlled clinical study.

Methods: Eyes (1000) were randomized to placebo (497) or nepafenac 0.3% (503) used once daily, post-operatively for 5 weeks at two ophthalmology clinics. Diagnosis of PCME was made by clinical, ocular coherence tomography (OCT), and with fluorescein angiography confirmation. Correlation of PCME to NSAID use and the presence of pre-operative risk factors for PCME were assessed including, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membrane, macular degeneration, retinal detachment repair, and prostaglandin use.

Results: PCME was the most common complication associated with routine cataract surgery (4.2% with PCME risk factors, 2.0% with risk factors excluded). Topical nepafenac 0.3% significantly reduces the incidence of PCME compared to placebo when used after routine cataract surgery (p = .0001). When patients with pre-operative risk factors are excluded, the incidence of PCME between treatment and placebo groups is equivalent (p = 0.31). PCME relative risk (RR) was most significant in contralateral PCME (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7), and epiretinal membrane (RR 5.7). Prostaglandin use and previous retinal detachment were not shown to increase risk.

Conclusion: Pseudophakic cystoid macular edema is common after phacoemulsification cataract surgery. Topical nepafenac 0.3% reduces PCME in patients with pre-operative risk factors for PCME compared to placebo but shows no benefit in patients without pre-operative risk factors.

Trial registration: NIH ClincalTrials.gov retrospectively registered January 15, 2017, NCT03025945 .

Figures

Fig. 1
Fig. 1
Post-operative change in macular volume in patients without risk factors (95% CI)
Fig. 2
Fig. 2
Post-operative change in macular volume in patients with risk factors (95% CI)

References

    1. Henderson B, Yong Kim J, Ament C, Ferrufino-Ponce Z, Gabowska A, Cremers S. Clinical pseudophakic macular edema; Risk factors for development and duration after treatment. J Cataract and Refractive Surgery. 2007;33:1550–8. doi: 10.1016/j.jcrs.2007.05.013.
    1. Lobo C, Faria P, Soares M, Bernardes R, Cunha-Vas J. Macular alterations after small incision cataract surgery. J Cataract and Refractive Surgery. 2004;30:752–60. doi: 10.1016/S0886-3350(03)00582-0.
    1. Vukicevek M, Franzco T, Franzco S. Prevalence of optical coherence tomography-diagnosed post-operative cystoids macular edema in patients following uncomplicated phaco-emulsification cataract surgery. Clin Exp Ophthalmol. 2012;40:282–7. doi: 10.1111/j.1442-9071.2011.02638.x.
    1. Almeida D, Khan Z, Xing L, Bakar S, Rahim K, Urton T, El-Defrawy S. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J Cataract Refract Surg. 2012;38:1537–43. doi: 10.1016/j.jcrs.2012.04.034.
    1. Mathys KC, Cohen KL. Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular edema. Eye. 2010;24:90–6. doi: 10.1038/eye.2009.10.
    1. Wittpenn J, Silverstein S, Heier J, Kenyon K, Hunkeller J, Earl M. A Randomized Masked Comparison of Topical Ketorlac 0.4% Plus Steroid vs Steroid Alone in Low Risk Cataract Surgery Patients. Am J Ophthalmology. 2008;146:554–60. doi: 10.1016/j.ajo.2008.04.036.
    1. Eriksson U, Alm A, Bjarnhall G, GranstamE MA. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmology. 2011;249:349–59. doi: 10.1007/s00417-010-1484-9.
    1. Gaynes B, Fiscella R. Topical Nonsteriodal Anti-inflamatory Drugs for Ophthalmic Use. Drug Saf. 2002;25:233–50. doi: 10.2165/00002018-200225040-00002.
    1. Wolf E, Braunstein A, Shih C, Braunstein R. Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepefanac. J Cataract Refractive Surgery. 2007;33:1546–9. doi: 10.1016/j.jcrs.2007.05.018.
    1. Almeida D, Johnson D, Hollands H, Smallman D, Baxter S, Eng K, Kratky V, Hove M, Sharma S, El-Defrawy S. Effect of prophylactic nonsteroidal anti-inflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery. J Cataract Refract Surg. 2008;34:64–9. doi: 10.1016/j.jcrs.2007.08.034.
    1. Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmology. 2005;89:1420–2. doi: 10.1136/bjo.2005.073817.
    1. Hee Suh M, Mo Seo J, Park K, Yu H. Associations Between Macular Findings by Optical Coherence Tomography and Visual Outcomes After Epiretinal Membrane Removal. Am J Ophthalmology. 2009;147:473–80. doi: 10.1016/j.ajo.2008.09.020.
    1. Donnenfeld E, Nichamin L, Hardten D, Raizman M, Trattler W, Rajpal R, Alpern L, Felix C, Bradford R, Villanueva L, Hollander D, Schiffman R. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmology. 2010;151:420–6. doi: 10.1016/j.ajo.2010.09.003.
    1. Henderson B, Gayton J, Chandler S, Gow J, Klier S, McNamara T. Safety and Efficacy of Bromfenac Ophthalmic Solution (Bromday) Dosed Once Daily for Postoperative Ocular Inflammation and Pain. Am Acad Ophthalmol. 2011;118:2120–7.
    1. Mukai K, Matsushima H, Gotoh N, Aose M, Satoshi W, Wataru T, Matsui E, Nagata M, Senoo T. Efficacy of ophthalmic nonsteroidal anti-inflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification. J Cataract Refract Surg. 2009;35:1614–8. doi: 10.1016/j.jcrs.2009.03.054.
    1. Miyake K, Ibaraki N. Prostaglandins and Cystoid Macular Edema. Surv Ophthalmol. 2002;47:S203–18. doi: 10.1016/S0039-6257(02)00294-1.
    1. Hariprasad S, Akduman L, Clever J. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1% Clin Ophthalmol. 2009;3:147–54. doi: 10.2147/OPTH.S4684.
    1. Warren K, Fox J. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina. 2008;28:1427–34. doi: 10.1097/IAE.0b013e31817e7ead.
    1. Barber B, Strahlman E, Laibovitz R, Guess H, Reines S. Validation of a questionnaire for comparing the tolerability of ophthalmic medications. Ophthalmology. 1997;104:334–42. doi: 10.1016/S0161-6420(97)30314-5.
    1. Tzelikis P, Vieira M, Alves M, et al. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study. Br J Ophthalmol. 2015;99:654–8. doi: 10.1136/bjophthalmol-2014-305803.
    1. Miyake K, Ota I, Maekubo K. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34–40. doi: 10.1001/archopht.117.1.34.
    1. Guo S, Patel S, Zarbin M. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123–37. doi: 10.1016/j.survophthal.2014.08.005.
    1. Chu C, Johnston R, Buscombe C, Sallam A, Mohamed Q, Yang Y. Risk Factors and Incidence of Macular Edema after Cataract Surgery. Ophthalmology. 2016;123:316–23. doi: 10.1016/j.ophtha.2015.10.001.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다